EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE‐303 Open‐Label Study

James E Ip iD, Benoit Coutu, John H Ip, Peter A Noseworthy iD, Maria L Parody, Farhad Rafii, Samuel F Sears iD, Narendra Singh, Bruce S Stambler iD, Naeem K Tahirkheli, Juan Agudelo-Uribe iD, Derek Hu und 5 weitere

Journal of Cardiovascular Electrophysiology · 2025

DOI: 10.1111/jce.70086 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2025. Verfasst von James E Ip und 16 weiteren Autor:innen. Beteiligte Einrichtung: New York Presbyterian Hospital, Weill Cornell Medicine, New York, USA. Hauptthemen laut MEDLINE: Anti-Arrhythmia Agents, Heart Rate, Tachycardia, Paroxysmal, Tachycardia, Supraventricular. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This study was funded by Milestone Pharmaceuticals Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Etripamil is a fast‐acting intranasally self‐administered calcium‐channel blocker developed for termination of paroxysmal supraventricular tachycardia (PSVT). Prior studies have demonstrated safety and efficacy of etripamil for PSVT termination following an initial medically supervised test dose during sinus rhythm. NODE‐303 is an open‐label, single‐arm study that evaluated etripamil for multiple, at‐home PSVT episodes, without test dose before first use.

Methods

Patients applied an ECG monitor at symptom onset and self‐administered etripamil (70 mg) if a vagal maneuver was unsuccessful. ECG monitoring occurred for ≥ 1 h following study drug administration. A repeat 70‐mg dose was introduced during the study for symptoms persisting 10 min after the first dose. Safety measures included treatment‐emergent adverse events (TEAEs) and ECG arrhythmia‐surveillance. Efficacy measures were captured for PSVT termination during treatment of each of the multiple episodes.

Results

1054 perceived PSVT episodes were etripamil‐treated in 503 of 1116 patients enrolled. TEAEs within 24 h were mostly mild or moderate and localized: 30.2% of patients experienced nasal discomfort, nasal congestion (13.9%), rhinorrhea (13.1%), epistaxis (7.4%). TEAE frequencies decreased across multiple PSVT episodes and were similar for single versus repeat doses. For first PSVT episodes, 70.5% of patients converted to sinus rhythm by 60 min post etripamil (median time to conversion = 18.3 min [14.2–25.6]). Conversion in earlier episodes was consistently predictive of conversion in subsequent episodes.

Conclusions

Etripamil nasal spray self‐administered in a real‐world setting was well tolerated, effective, and had a consistent safety profile as a single‐ or repeat‐dose regimen across multiple PSVT episodes. Trial Registration: ClinicalTrials.gov NCT04072835

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Arrhythmia AgentsHeart RateTachycardia, ParoxysmalTachycardia, SupraventricularAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAction PotentialsAdministration, IntranasalElectrocardiographyNasal SpraysRecurrenceTime FactorsTreatment Outcome

Stichwörter der Autor:innen

NODE‐303calcium channel blockeretripamilnasal sprayparoxysmal supraventricular tachycardiaself‐administered

Substanzen

Anti-Arrhythmia AgentsNasal Sprays

Autor:innen und Institutionen

  • New York Presbyterian Hospital, Weill Cornell Medicine, New York, USA.
  • Montreal University Hospital Center, Montreal, Canada.
  • Sparrow Thoracic and Cardiovascular Institute, Edward W. Sparrow Hospital Association, Lansing, MI, USA.
  • Mayo Clinic, Rochester, USA.
  • Hospital San Roque, San Roque, Argentina.
  • Interventional Cardiology Medical Group, West Hills, CA, USA.

ORCID-Profile: James E Ip, Peter A Noseworthy, Samuel F Sears, Bruce S Stambler, Juan Agudelo-Uribe

Förderung

  • This study was funded by Milestone Pharmaceuticals Inc.

Zitieren

APA

Ip, J. E., Coutu, B., Ip, J. H., Noseworthy, P. A., Parody, M. L., Rafii, F., Sears, S. F., Singh, N., Stambler, B. S., Tahirkheli, N. K., Agudelo-Uribe, J., Hu, D., Shardonofsky, S., Sheikh, M. B., Holz, A., Bharucha, D. B., & Camm, A. J. (2025). Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE‐303 Open‐Label Study. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.70086

Vancouver

Ip JE, Coutu B, Ip JH, Noseworthy PA, Parody ML, Rafii F, et al. Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE‐303 Open‐Label Study. Journal of Cardiovascular Electrophysiology. 2025. doi:10.1111/jce.70086

BibTeX
@article{Ip2025,
  author = {Ip, James E and Coutu, Benoit and Ip, John H and Noseworthy, Peter A and Parody, Maria L and Rafii, Farhad and Sears, Samuel F and Singh, Narendra and Stambler, Bruce S and Tahirkheli, Naeem K and Agudelo-Uribe, Juan and Hu, Derek and Shardonofsky, Silvia and Sheikh, Muhammad B and Holz, Anita and Bharucha, David B and Camm, A John},
  title = {Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE‐303 Open‐Label Study},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2025},
  doi = {10.1111/jce.70086}
}
Kostenlos starten →